Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.

Cancer Sci · 2016 · PMC4768392 · PMID 26663719

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

showed a trendP = 0.096so close (0.05 < p ≤ 0.1)

Docetaxel clearance was significantly different between Category 1 and Category 2 (corrected P = 0.022) or Category 3 (corrected P < 0.001) and between Category 2 and Category 3 before adjustment (nominal P = 0.0431), which showed a trend after correction for multiple comparison (corrected P = 0.096).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.